Avalo Therapeutics (AVTX)Orbimed Advisors LLC reduced its stake -162K shares

1.19M

Shares reported · -162K vs prior quarter

0.44%

Disclosed portfolio weight

$21.6M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news

What came next

1. Mar 23, 2026Company filing · Form 8-K · ResultsReported its results
2. Mar 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”), each notified the Company of his decision to not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”).”
3. Apr 26, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
4. May 5, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
5. May 13, 2026Company filing · Form 8-K · ResultsReported its results
6. Jun 2, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“(e) Equity Plan Amendments As noted in Item 5.07 below, at the Avalo Therapeutics, Inc. (the “Company”) 2026 annual meeting of stockholders (the “Annual Meeting”), the Company’s stockholders approved the Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan (the “A&R 2016 ESPP”).”
7. Jun 11, 2026Company filing · Form 8-K · Unregistered shares, Shareholder rightsChanged a top executive or board member, and sold new shares without registering them (and 2 more items)“On June 12, 2026 (the “Effective Date”), the Company entered into amendments to employment agreements with Garry A. Neil, M.D., the Company’s Chief Executive Officer, Christopher Sullivan, the Company’s Chief Financial Officer, Mittie Doyle, M.D., FACR, the Company’s Chief Medical Officer and Taylor Boyd, Chief Business Officer (together, the “Employment Agreement Amendments”).”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Avalo Therapeutics

For Avalo Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AVTX page.

How this filing works

• SEC Form 13F

Other disclosures at Avalo Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 13F-HRFeb 14, 2025
• SEC Form 13F-HRNov 14, 2024

Everything OQRO holds on this company is on its AVTX page.